Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
Crossref DOI link: https://doi.org/10.1007/s11095-021-03024-w
Published Online: 2021-03-17
Published Print: 2021-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Minichmayr, Iris K.
Karlsson, Mats O.
Jönsson, Siv http://orcid.org/0000-0001-8240-0865
Funding for this research was provided by:
Horizon 2020 Framework Programme (No. 668353 (U-PGx))
Text and Data Mining valid from 2021-03-17
Version of Record valid from 2021-03-17
Article History
Received: 22 December 2020
Accepted: 26 February 2021
First Online: 17 March 2021